Research programme: antibody-drug conjugates - Bayer HealthCare
Alternative Names: Anti-C4.4a antibody-drug conjugates; Anti-C4.4a-ADC; Anti-LY6-PLAUR domain containing 3 antibody-drug conjugates; Antibody-Eg5 inhibitor conjugates; Antibody-KIF11 inhibitor conjugates; Antibody-kinesin spindle protein inhibitor conjugates; Antibody-KSP inhibitor conjugates; FGFR2-ADCLatest Information Update: 01 Aug 2024
At a glance
- Originator Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals; Seagen
- Class Antibodies; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins
- Mechanism of Action Apoptosis stimulants; KIF11 protein inhibitors; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Dec 2023 Seagen has been acquired by Pfizer
- 28 Sep 2018 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 01 Apr 2017 Pharmacodynamics data from preclinical trials in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)